-
- Oncology
- Non-Profit/Patient Advocacy Group
This is a three day course requiring attendance on all three days. "Advanced Business Development "(ABD) is a long-running course focusing on all key aspects of transactions in the biopharma industry. ... -
Translating Nobel Prize science into the clinic
-
Copays Kill: How Cost Sharing Undermines Health
-
Rescuing Promising but Shelved Assets: New Models to Overcome Barriers and Put Unmet Patient Needs First
-
35th Biotech Beyond Borders Report: Are Capital Markets Finally Coming Back?
-
Next-Gen Advocates: Patients & Families Driving Breakthroughs in Rare Disease Drug Development
-
AI in biologics drug discovery: analyzing the competitive landscape, technical approaches, and the industry's role.
-
Novel Oncology Targets & Modalities Enter the Clinic - What’s Next?
-
Fueling Innovation: Strategies for Funding Academic Spin Outs
-
Foundation Models for Genomics: Current Advances and Future Directions
-
Trusting the Machines: Designing Transparent AI Solutions for Healthcare
-
Achieving Synergy: A Roadmap to Successful Academia-Industry Collaborations from Discussion to Implementation
-
“Journey Into the [Un]validated” – a practical guide to partnering early with pharma on novel drug modalities!
-
The Priority Review Voucher Program: Incentivizing Neglected Disease Research and Promoting Biotech Investment and Development for More than a Decade
-
The New Era of Project Optimus: Implications for Oncology Development Strategy
-
Advanced Business Development
-
We’ve Entered a New Era of Neuropsychiatry: Precision in Practice
-
Patient Diversity and Access to New Medicines – Can AI improve access in disadvantaged patient populations and optimize the economics of medical innovation?
-
Flow of Capital to Women's Health : from innovation to patient
-
What are the opportunities and challenges for the new generation of TechBio partnerships powered by Generative and Foundational AI?
-
US Legal and Regulatory Framework, Challenges, and Opportunities for AI Use in Pharma Product Development
-
From Discovery to Deals: Bridging the Valley-of-Death with a Molecule-to-Medicine Expressway
-
The Innovation Race vs. Regulatory Pace: What to do when innovation outpaces regulation
-
Oncology investment themes: where is the market putting its money?
-
Undermining Innovation: How antimicrobial resistance imperils patients and threatens the future of medicine
-
Best Practice for Genuine Sustainability- Pharmaceutical Companies in Latin America are Implementing Successful Sustainable Practices Without Resorting to Greenwashing.
-
Shifting Attitudes Toward Vaccines Among Lawmakers
-
Commercializing SBIR/STTR Technologies
-
Expanding the reach of Cell Therapies: Shaping the Future of Autoimmune Disease Treatment
-
Celebrating Women Leading Innovation in Biopharma
-
Biotech M&A 2025: What’s Driving Deal Making in The New Environment
-
Business Development Fundamentals
-
Navigating regulations to bring cell/gene therapies to patients in Europe and Middle East
-
Become a Biotech or MedTech Entrepreneur
-
The Role of Small Investors in the Biotech Funding Landscape – a global perspective
-
Guide to Raising Institutional Private Capital
-
Trends in Dealmaking: Shaping Drug Development Through External Innovation
-
Product & Company Valuation
-
Commercialization Readiness From Preclinical to 1st Launch: The First Time CEOs Playbook
-
Program Committee
-
Master the Art of Business Development Negotiations
-
Ethical and Practical Considerations for Multi-National Rare Disease Clinical Trials
-
Optimizing Clinical Trial Design and Execution for Rare Diseases
-
Policy Outlook: All Eyes on Intellectual Property Rights
-
Building Winning Presentations and Using Emotional Intelligence as a Tool for Success
-
Platform Licensing: Biotech and Pharma Perspectives
-
Leveraging the Accelerated Approval Pathway for Rare Diseases
-
Profit and Access: Groundbreaking Strategies to Make Medicines Available in Resource-Challenged Markets
-
Companies should embrace RWE strategies early and often to enhance shareholder and stakeholder value throughout drug development and commercialization
-
Fuel Your Innovative Cancer Breakthrough: From Unlocking Dilutive and Non-Dilutive Funding to Fostering Fruitful Partnerships
-
Rapid response capabilities of global health and biosecurity countermeasures during outbreaks- leveraging public private partnerships.
-
How to Best Scale CGT Manufacturing: Bringing Together Disparate Approaches
-
It’s not “Just the Flu”: Harnessing innovation to save lives
-
Platform Power: How Genetic Medicine Technologies Are Changing Expectations for Medicine
-
The New Era of Mega Blockbusters: Advancing Drug Development for Broader Patient Impact
-
Examining innovative business models for creating sustainable network and capabilities for public health and biosecurity countermeasures
-
The “RNAissance” Era – Recent Breakthroughs, Future Prospects, and Challenges of RNA Therapeutics
-
Co-Discovery and Co-Development Partnerships to Accelerate Next-Generation Medicines
-
In Vivo CARs: Unlocking the Potential of Immune Cell Programming in Oncology and Beyond
-
European biotech: Unlocking investment opportunities
-
Weight Loss for Longevity? How metabolic drugs are disrupting chronic disease and improving healthspan
-
INTELLECTUAL PROPERTY CONSIDERATIONS FOR INVENTIONS MADE BY, OR INVOLVING, ARTIFICIAL INTELLIGENCE
-
Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and Bottlenecks
-
“What If?” Preparing for Cybersecurity Risks Begins by Understanding AI’s Role in Attacks and Defense
-
Scalable Biomanufacturing for Living Medicines: Pioneering the Future Today
-
Understanding and Mitigating the Consequences of Loper Bright, Corner Post & Judicial Activities on Drug Development, Commercialization, and Investment
-
AI in Biopharma: What’s Working and What’s left to prove
-
Integrating AI-Driven Drug Discovery to Improve R&D Supply Chain Efficiency
-
Accelerated Approval and Patient Need: The Value of Earlier Access
-
Bridging the Innovation Valley of Death – a Call for Greater Pharma-Biotech-Academia Collaboration
-
Healthcare AI Opportunities and Headwinds at NIH and the Ecosystem at Large: Fulfilling the Promise or Machine Learning Impaired?
-
Preparing for the next generation in antimicrobial resistance: Combining traditional with non-traditional therapeutic approaches to tackle an ongoing pandemic
-
We Still Need the People: AI/ML Drug Discovery is Here to Stay, but we Could be its Rate Limiting Factor
-
In Pursuit of Health Equity: How Industry Has Evolved Its Focus On This Critical Healthcare Challenge
-
Evolving from Patient Centricity to Integrated Patient Engagement- Change Management Experience and Key Learnings
-
CI for the Biotech Journey: Applying Lessons from Pharma
-
Advancing innovative risk-stratification tests that impact treatment pathway decisions: challenges in overcoming barriers to entry
-
Beyond the Contract: Building Successful Biotech Partnerships
-
Test Session
-
Revolutionizing Drug Development: Harnessing New Approach Methodologies (NAMs) for a Safer Future in Medicine
-
Beyond Innovation: Supercharging America's Biomanufacturing Infrastructure
-
Building a Diverse Life Science Workforce for the Nation’s Bioeconomy: 4 industry-academic models
-
Building and sustaining a comprehensive education and workforce development continuum to support an evolving industry: Massachusetts shares its lessons
-
Bridging the biodata gap: Revolutionizing AI's impacts in biopharma by creating ‘digital twins’ of the natural world
-
Weighing in on Weight Loss Medicine
-
Innovative Patient-Focused Models for Accelerating Rare Drug Development
-
An Eye on I&I: Innovations Fueling Growth
-
Closing the practice gaps in precision oncology – what are the practical solutions?
-
Global Puzzle: Decoding Cell Therapy Classifications in Europe and the USA
-
Funding Workforce Diversity in Biomedical Innovation.
-
Inflation Reduction Act (IRA) Litigation: Past and Future Impact on the Price Negotiation Framework
-
Shaping Sustainability Strategies for Lasting Value
-
Psychedelics Are Going Mainstream. Are you ready for it?
-
Recognizing the “Why?” Behind Our Medicines: Patient Connection as a Motivator for Impact
-
Expediting Impact: Leveraging the Patient Voice for Enhanced Clinical Trial Design and Accelerated Regulatory Approvals
-
Overcoming Economic Challenges to Rare Disease Drug Development
-
Attacking Cancer from All Angles: From ADCs to Immunotherapy
-
Patient-reported Outcomes are Front and Center for Drug Development AND with the FDA and the CDC
-
How VCs Evaluate Risk in Early Stage Startups
-
Investors’ Perspectives – AI and Digital Health Investment Trends in 2025
-
Carving out your ground in Immunology & Inflammation (I&I)
-
Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?
-
Effective Use of the New European Patent System as Part of your Global Patent Strategy
-
From Skepticism to Opportunity: Building Investor Confidence in First-in-Class and First-in-Disease Drug Innovation
-
Cracking the Code: Effective Biotech and Pharma Partnerships Unveiled
-
Preparing for an IPO: Best Practices for Success
-
Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug Discovery
-
Who Are Today’s Biotech Underdogs and What It Will Take for Them to Succeed
-
Next-Gen Medicine: How Gene Editing and Epigenetics are Revolutionizing Health, Longevity, and Organ Transplantation
-
Next-Generation Alzheimer's Disease Therapies
-
Physician and patient perspectives on the impact of the Inflationary Reduction Act on drug development, access, and innovation
-
An Investor and a Value Assessor Walk into a Bar
-
Unlocking the Future: Opportunities and Challenges in Advanced Biologics Manufacturing
-
Improving and Restoring Vision in Blinding Eye Diseases
-
Partnering with the U.S. Government to Achieve Our National Security Mission
-
The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
-
Affiliate Event Test